Home/ConSynance Therapeutics/Jill Rasmussen, MD

JR

Jill Rasmussen, MD

Acting Medical Director

ConSynance Therapeutics

Therapeutic Areas

Rare CNS Diseases Neuropsychiatry Neurodevelopmental Disorders

ConSynance Therapeutics Pipeline

Drug	Indication	Phase
CSTI-500	Prader-Willi Syndrome (Hyperphagia & Neurobehavioral Challenges)	Phase 2
CSTI-100 / HBS-102	Rare Neurological Disorders	Preclinical

Leadership Team at ConSynance Therapeutics

Shuang Liu, PhD

Sarah Sheldrick, PhD

Research Director

Strategic Advisor

View full ConSynance Therapeutics profile